S
has only Bouckaert and Moraes (8) to reverse the vasorecently been isolated, synthesized and constrictor activity of defibrinated blood in available in quantities sufficient to study perfusion experiments; its action against pure its pharmacologic actions. In a brief span of serotonin is evaluated here; e) Pitressin tends time several publications have appeared sugto oppose adrenergic blockade as Grimson (9) gesting that it may be important in normal and we (IO) have observed; its action against physiology.
In addition to a direct vasoconthe serotonin-blocking action of ergotamine strictor action, a ganglion-blocking action, is studied here; f) I-hydrazino-phthalazine diminishes the pressor and increases the depressor action of serotonin (I, I I) ; this effect is examined further; g) because of a structural similarity to serotonin, calycanthine, sempervirine, quinamine, serpentine and lysergic acid were studied. and one initiating a von Bezold-like effect, serotonin has a strong peripheral inhibitory effect on neurogenic vasoconstriction (I, 2). Serotonin also inhibits tonic contraction in invertebrate smooth muscle (3), and demonstration of its presence there has prompted the suggestion that it may occur as a normal relaxing agent. It appears in blood with clotting (4) and it has been found in mammalian spleen and intestinal mucosa (enteramine) (5, 6); work now in progress in this laboratory strongly suggests its presence in other mammalian tissues.
As evidence accumulates that may establish serotonin an important place in vascular homeostasis, study of the modifying effects of other drugs on vascular response to serotonin becomes cogent. Drugs to be examined are: a) the antimetabolites, z-methyl-3-ethyls-aminoindole and 2-methyl-3-ethyl-s-nitroindole, which have been shown by Woolley and Shaw (7) to oppose the pressor action of serotonin.
We wished to confirm and extend their observations and compare these drugs with other blocking agents; b) the antihistamine drugs were used to determine whether the hypotensive action of serotonin in cats and neurogenic hypertensive dogs (I) might be due, in part, to release of histamine; c) because of structural similarities between some of the adrenergic-blocking agents and serotonin, the effectiveness of several is compared with that of other serotonin-blocking agents; d) ergotamine has been shown by Heymans, When larger doses of 20 mg/kg were given by continuous infusion, but over a period of z or more hours, there was often little change in response to posing action was I hour or more in most exserotonin unless the rate of the infusion was periments but both degree and persistence of increased: pressor response to serotonin was effect varied greatly from animal to animal. In one experiment, 6 gm were given in divided doses the day before and 2 gm given 2 hours before testing with slight increase instead of ib. decrease in vascular response to serotonin, angiotonin and nor-adrenaline. failed to show its depressant action on serotonin response in these preparations; more often, the pressor action of serotonin was augmented by repeated doses of Benodaine.
Yohimbine (4 mg/kg) reversed the pressor action of serotonin in dogs when response to nor-adrenaline was reduced only slightly. The effect was best seen when response to serotonin had previously been made strongly pressor by ganglion blockade with hexamethonium.
Reversal was not prolonged, lasting an average of from [10] [11] [12] minutes. diminished or reversed the pressor action of serotonin in normal dogs, but the effect was less striking since control responses were often biphasic.
EFFECT
Response to serotonin was entirely pressor 24 hours after section of the spinal cord at 05 and acute section of the vagus nerves, but these responses were also inhibited by ergotamine; inhibition was not as great, however, as immediately after interruption of sympathetic nervous activity.
To be sure that inhibition of the pressor activity of serotonin by ergotamine takes place at the blood vessel, the blocking action was measured in perfused dog's legs and dog's kidneys according to techniques described previoudv (2).
Both kidney and leg (in sepa-I rate experiments)
were perfused with the animal's own blood rather than with that of a donor animal. Change in vascular resistance was measured from a mercury manometer introduced into the perfusion circuit between a roller-type constant-output pump and the perfused leg or kidney. Care was taken not to damage the nerve supply to either leg or kidney.
When sympathetic outflow was inhibited by giving 300 mg of procaine intracisternally, responses to serotonin injected into the perfusion system were strongly and purely constrictor in both kidney and leg. Following injection of erogtamine into the animal's body, systemic response to serotonin in both leg and kidney was reversed from vasoconstrictor to vasodilator. However, reversal of response to serotonin in the perfused leg and kidney was not as long lasting as in the body. Incubation of 0.05 mg of serotonin with o.ooo~-o.oog mg of ergotamine tartrate had no effect on its pressor activity.
Lysergic acid, one of the structural components of ergotamine, failed to block serotonin when given intravenously in doses of 0.2 mg/kg. Pitressin had a striking effect on response to serotonin after its reversal to depressor by ergotamine (table I) . During the prominent rise in arterial pressure after intravenous injection of I u or less of Pitressin, injection of serotonin then elicited a pressor response, usually as large or larger than the control response before its reversal by ergotamine. With subsidance of the pressor action of Pitressin, response to serotonin became progressively less pressor and more depressor so that when the action of Pitressin was exhausted, response to serotonin was again entirely depressor. Rise in pressure with Pitressin was not essential for this re-reversal of serotonin response. When, after serotonin response was made depressor by ergotamine, tachyphylaxis to Pitressin was induced-with the final pressure no different from the control value-response to serotonin was again pressor. Raising arterial pressure with other agents, such as renin or nor-adrenaline, did not cause serotonin response to become pressor when it while lowering arterial pressure 70 or more mm had been made depressor by ergotamine.
Hg* Experiments on the perfused innervated dog's leg demonstrated that the effect of Pitressin on serotonin response after reversal with ergotamine did not depend on increase in cardiac output that might have resulted from serotonin-induced vasodilation of the coronary vessels subsequent to their constriction by Pitressin. When response to serotonin was reversed by ergotamine in the perfused leg, injection of Pitressin into the perfusion circuit caused response to serotonin to become pressor.
Quinamine given intravenously in doses of 6 mg/kg had no effect on arterial pressure or vascular reactivity to serotonin, adrenaline, nor-adrenaline or Mecholyl (table I) Sempervirine nitrate given intravenously I mg/kg at a time, produced transient falls in pressure of from 14-20 mm Hg and did not significantly change vascular reactivity to serotonin after doses up to 3 mg/kg. Rapid injection of I .5 mg/kg or more often caused respiratory paralysis.
Serpentine in doses of up to 7.0 mg/kg failed to modify vascular reactivity to serotonin Serotonin characteristically evokes pure fall in arterial pressure in dogs made hypertensive by section of the buffer nerves (2). This depressor response was shown to be due to peripheral inhibition of neurogenic vasomotor tone. TEA and hexamethonium, by inhibiting neurogenic vasoconstriction, cause response to serotonin to become pressor. Benodaine also interferes with vasoconstriction of neurogenic origin and, in doses of 2-4 mg/kg, reduced the depressor action of serotonin in neurogenic hypertensive dogs.
Fall in pressure due to serotonin does not depend to any great extent upon release of histamine since Phenergan (2 mg/kg) prevented the hypotensive action of 0.1: mg of histamine without modifying that of serotonin. Small doses of ergotamine tartrate (0.12-0.5 mg) raised arterial pressure but had no effect on the hypotensive action of serotonin.
Production of curare-like neuromuscular paralysis with MO 2747 (Mytolon) abolished the respiratory stimulant effect of serotonin but had no effect on the depressor response to serotonin in neurogenic hypertensive dogs.
Infusion of the serotonin competitor, 2-methyl-3-ethyl+aminoindole HCl, in doses of mg/kg had no, or slight, effect on the hypotensive action of serotonin in neurogenic hypertensive dogs. What little effect was occasionally observed depended on volume of the infusion, since rapid administration of large amounts of saline often prevented almost completely the hypotensive action of serotonin.
z-Methyl-3-ethyl-s-nitroindole was also ineffective when fed in gelatin capsules in doses of 250 mg two times a day for IO days in reducing the hypotensive action of serotonin in neurogenic hypertensive dogs. It also had no effect on arterial pressure or response to angiotonin. DISCUSSION 2-Methyl-3-ethyl+aminoindole was synthesized by Woolley and Shaw (7) because its structure should enable it to compete with serotonin at vascular receptors. They proved their hypothesis experimentally and our results are confirmatory. We found it necessary to administer the antimetabolites rapidly and wait a short time before competition was apparent. The latent period possibly depends upon a metabolic change requiring time.
The pressor action of serotonin was readily blocked by the antimetabolites but the hypotensive action in either cats or neurogenic hypertensive dogs was unmodified or even augmented. The latter effect depends upon peripheral inhibition of neurogenic vasoconstriction and a von Bezold-like reflex. The receptors, or points of action, must, therefore, differ from those mediating the vasoconstrictor action of serotonin, In these respects the antimetabolites behave as do the adrenergicblocking agents which prevent the pressor action of adrenaline and nor-adrenaline but do not change, or increase, the depressor action. It is possible that serotonin, in addition to its other actions, may, like adrenaline, have both vasoconstrictor and direct vasodilator actions, the latter being unmasked by blocking the constrictor effect.
Serotonin receptors that mediate vasoconstriction and respiratory stimulation must have similarity since the antimetabolites were able to prevent both responses.
Blockade of response to DMPP and TMAI, both ganglion-stimulating agents, by the serotonin antimetabolites suggests an action at the ganglia since adrenaline and nor-adrenaline are not blocked. Further evidence that they affect activity of the sympathetic nervous system is the observation that they reduce or reverse the hypotensive action of TEA in normal dogs. This might, however, be due to reflex inhibition of sympathetic outflow mediated by the buffer reflexes since the antimetabolites had a sustained pressor effect.
The structure of 5-hydroxyindoleacetic acid is not sufficiently close to that of serotonin to allow competition; it had little effect on vascular response.
We are unable to explain why oral administration of 2,3-dimethyl-5-nitroindole failed to inhibit the response to intravenouslyadministered serotonin as found by Woolley and Shaw (7). Perhaps fasting of our dogs when they received the antimetabolites would have changed the results. The antimetabolite also caused no change in arterial pressure in one patient with malignant hypertension or in dogs with experimental neurogenic hypertension.
The other serotonin-blocking agents examined, except for the antihistamines, behave similarly: those that effectively blocked the pressor action of serotonin augmented the depressor action-possibly by unmasking it. The ganglion-blocking agents, on the other hand, inhibited the depressor action and augmented the pressor action of serotonin in normal dogs. Elimination of the depressor action depended on the prior elimination of vasoconstriction by the ganglion-blocking agents. But after their administration it was possible to reverse by 10.220.33.6 on April 20, 2017 http://ajplegacy.physiology.org/ deeply the pressor action of serotonin by any one of several agents. Thus the mechanisms of these two depressor actions must be different.
The partial inhibition of the pressor action of serotonin in dogs by the antihistamine drugs may find some basis in competition by the common C-CH2-CH2-NH2 structure. Reduction of the hypotensive action of serotonin in cats by the antihistamine drugs is most likely attributable to their atropine-like action with elimination of the von Bezold reflex and to reduction of neurogenic vasoconstrictor tone, since they also reduced the hypotensive action of TEA. Serotonin possibly belongs to the histamine-releasing class of drugs such as described by Macintosh and Paton (13)~ but we found no parallelism between inhibition of histamine and depression of the hypotensive action of serotonin in either cats or neurogenic hypertensive dogs. If such action exists, it must be of only secondary importance in vascular response to quick injection of serotonin.
The structural similarity of the ergotamine and yohimbine molecules to serotonin suggest that their blocking action may be due to interference by competition.
It is likely that rGzgs A and B in the lysergic portion of ergotamine are the structures essential for competition, though lysergic acid alone has no competitive action against serotonin in intact animals. It is puzzling that Regitine antagonizes the pressor action of serotonin in normal dogs but not in dogs after inhibition of sympathetic nervous activity. And chronic inactivation of the sympathetic nervous system modified the effectiveness of nearly all the serotonin-blocking agents. While serotonin blockade was easy immediately after chemical blockade of sympathetic ganglia or administration of intracisternal procaine, it was difficult and sometimes impossible 24 hours after section of the spinal cord at C6. Thus, the same mechanisms that make adrenergic blockade so much more difficult after section of the spinal cord also seem to modify the effectiveness of the serotonin-blocking agents. Benodaine, while effective in reducing the pressor action of serotonin in normal dogs, had no effect, or even increased the action of serotonin in dogs after section of the spinal cord. Ergotamine easily reversed the pressor action of serotonin after ganglion blockade but did so with great difficulty, if at all, after cord section. given intravenously, slightly raised arterial pressure and blocked the pressor but not the depressor action of serotonin in dogs and cats and prevented its respiratory-stimulant action in dogs. They had an irregular blocking action against the pressor effect of DMPP, THAI, and cinobufotenine.
2-Methyl-3-ethyl-5-nitroindole given by mouth failed to block the vascular action of serotonin in normal dogs and failed to alter arterial pressure in neurogenic hypertensive dogs and in one patient with malignant hypertension.
The antihistamine drugs (Benadryl, Thenfadil and Phenergan) slightly reduced the pressor action of serotonin without diminishing the depressor in normotensive or neurogenic hypertensive dogs. In cats, the depressor action was reduced but was not correlated with reduction of response to histamine.
Small doses of ergotamine reversed the pressor action of serotonin while augmenting response to other vasopressor drugs. Perfusion experiments demonstrated that ergotamine blockade was at the peripheral blood vessel. Pitressin opposed the serotonin-blocking action of ergotamine in both body and perfused extremity.
Serotonin-blocking drugs were effective immediately after inactivation of the sympathetic nervous system but were much less so 24 hours after section of the spinal cord at C6. Benod&e reduced the pressor action of serotonin
